Overview

Study of Acamprosate in Fragile x Syndrome

Status:
Completed

Trial end date:
2018-11-08

Target enrollment:

Participant gender:

Summary

In this research study we want to understand the effectiveness of a drug treatment, acamprosate, for interfering symptoms (i.e., inattention/hyperactivity, social impairment) associated with Fragile X Syndrome (FXS).

Phase:

Phase 1

Details

Lead Sponsor:

Children's Hospital Medical Center, Cincinnati

Collaborator:

Rush University Medical Center

Treatments:

Acamprosate